DE60019411T2 - Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden - Google Patents

Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden Download PDF

Info

Publication number
DE60019411T2
DE60019411T2 DE60019411T DE60019411T DE60019411T2 DE 60019411 T2 DE60019411 T2 DE 60019411T2 DE 60019411 T DE60019411 T DE 60019411T DE 60019411 T DE60019411 T DE 60019411T DE 60019411 T2 DE60019411 T2 DE 60019411T2
Authority
DE
Germany
Prior art keywords
host cell
bacteriophage
protein
temperature
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019411T
Other languages
German (de)
English (en)
Other versions
DE60019411D1 (de
Inventor
A. Vitaliy KORDYUM
I. Svetlana CHERNYKH
Y. Irina SLAVCHENKO
F. Oleksandr VOZIANOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiovascular Bio Therapeutics inc Las Vega Us
Phage Biotechnology Corp
Original Assignee
Phage Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phage Biotechnology Corp filed Critical Phage Biotechnology Corp
Publication of DE60019411D1 publication Critical patent/DE60019411D1/de
Application granted granted Critical
Publication of DE60019411T2 publication Critical patent/DE60019411T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60019411T 1999-05-25 2000-05-24 Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden Expired - Lifetime DE60019411T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/318,288 US6268178B1 (en) 1999-05-25 1999-05-25 Phage-dependent super-production of biologically active protein and peptides
US318288 1999-05-25
PCT/US2000/040020 WO2000071731A1 (en) 1999-05-25 2000-05-24 Phage-dependent super-production of biologically active protein and peptides

Publications (2)

Publication Number Publication Date
DE60019411D1 DE60019411D1 (de) 2005-05-19
DE60019411T2 true DE60019411T2 (de) 2006-03-09

Family

ID=23237514

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019411T Expired - Lifetime DE60019411T2 (de) 1999-05-25 2000-05-24 Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden

Country Status (7)

Country Link
US (2) US6268178B1 (https=)
EP (1) EP1180153B1 (https=)
JP (1) JP2003500059A (https=)
AT (1) ATE293170T1 (https=)
AU (1) AU5049100A (https=)
DE (1) DE60019411T2 (https=)
WO (1) WO2000071731A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252818B2 (en) * 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
US6268178B1 (en) * 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
JP2004517607A (ja) * 2000-08-15 2004-06-17 ファージ バイオテクノロジー コーポレイション 生物学的に活性なヒト酸性線維芽細胞成長因子の産生方法および血管新生の促進におけるその使用
EP1309604B1 (en) * 2000-08-15 2007-03-28 Phage Biotechnology Corporation Phage-dependent superproduction of biologically active protein and peptides
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
WO2019068006A1 (en) * 2017-09-29 2019-04-04 The Charles Stark Draper Laboratory, Inc. CELLULAR LYSE CONTROLLED BY STIMULUS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276694C (https=)
IL59007A (en) 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
CA1209501A (en) 1982-09-16 1986-08-12 Nikos Panayotatos Expression vector
JPS5979746A (ja) 1982-10-30 1984-05-09 Mitsubishi Heavy Ind Ltd 加硫機用制御装置
SU1089119A1 (ru) * 1982-11-29 1984-04-30 Институт Молекулярной Биологии И Генетики Ан Усср Способ получени @ -лактамазы
GB2143238A (en) 1983-03-31 1985-02-06 Dr Anthony Stuart Breeze A method for enzyme liberation from bacterial cells
US4637980A (en) 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
CA1309044C (en) 1987-11-09 1992-10-20 Toshiya Takano Method of producing foreign gene products
IL92124A (en) 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
US5102797A (en) 1989-05-26 1992-04-07 Dna Plant Technology Corporation Introduction of heterologous genes into bacteria using transposon flanked expression cassette and a binary vector system
US5196318A (en) 1990-06-26 1993-03-23 The Texas A&M University System Precisely regulated expression of deleterious genes
NZ241311A (en) 1991-01-17 1995-03-28 Gen Hospital Corp Rna sequence having trans-splicing activity, plant strains
US5346830A (en) 1991-06-11 1994-09-13 The Center For Innovative Technology Gene expression system based on regulatory elements of bateriophage P2 and satellite phage P4
US5834233A (en) 1992-04-06 1998-11-10 Gx Biosystems A/S Method of limiting the survival of genetically engineered microorganisms in their enivronment
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US6268178B1 (en) * 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
EP1309604B1 (en) * 2000-08-15 2007-03-28 Phage Biotechnology Corporation Phage-dependent superproduction of biologically active protein and peptides
JP2004517607A (ja) * 2000-08-15 2004-06-17 ファージ バイオテクノロジー コーポレイション 生物学的に活性なヒト酸性線維芽細胞成長因子の産生方法および血管新生の促進におけるその使用

Also Published As

Publication number Publication date
JP2003500059A (ja) 2003-01-07
EP1180153B1 (en) 2005-04-13
US20010044133A1 (en) 2001-11-22
DE60019411D1 (de) 2005-05-19
US6268178B1 (en) 2001-07-31
US6794162B2 (en) 2004-09-21
EP1180153A1 (en) 2002-02-20
ATE293170T1 (de) 2005-04-15
AU5049100A (en) 2000-12-12
WO2000071731A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DE60127561T2 (de) Phagen-abhängige superproduktion biologisch aktiver proteine und peptide
DE3586858T2 (de) Transformation von aspergillus niger und dabei zu verwendende plasmide.
DE68928751T2 (de) Glykosylierte Polypeptide
DE3586189T2 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
DE3546806C2 (https=)
EP0023882B1 (de) Plasmidvektoren, Plasmide mit Genen für alkalische Phosphatasen und Bakterien, die letztere enthalten, ihre Herstellung und Verwendung
LV10309B (en) Method for enzymatic splitting of recombinant proteine with iga proteases, fusioned proteine,recombinant dna, cell
DE3382575T2 (de) Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden.
DE3687141T2 (de) Verfahren zur herstellung von peptiden.
DD203071A5 (de) Verfahren zur herstellung von rekombinant-dna-molekuele
DD212748A5 (de) Verfahren zur bildung doppelstraengiger, hybride human-leukozyten-interferone kodierender dns
DE3382789T2 (de) Tierische Interferone, Verfahren bei deren Herstellung, dieselben enthaltende Zusammensetzungen, kodierende DNS-Sequenzen hierfür und diese Sequenzen enthaltende Expressionsvektoren und dadurch transformierte Zellen.
DD209652A5 (de) Verfahren zur herstellung eines replikablen vektors
DE3404434A1 (de) Verfahren zur herstellung von proteinen, die dem diphtherietoxin entsprechen
DE69314574T2 (de) Megakaryozyten-Differenzierungsfaktor
DE60108102T2 (de) E. coli extrakt zur synthese von proteinen
EP0027662A1 (de) Eukaryotische Zellen und eukaryotische Protoplasten mit einem Gehalt an durch Lipidvesikel eingebrachter nackter DNA, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Gen-Produkten
DE69826864T2 (de) Vektor zur heterologen proteinexpression und verfahren zur extraktion rekombinanter proteine sowie zur isolierung rekombinanten insulins
DE60019411T2 (de) Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden
CH640268A5 (en) Process for the preparation of filamentous hybrid phages, novel hybrid phages and their use
EP0066857A2 (de) Verfahren zur Herstellung eines Mikroorganismus, welcher alpha-Galactosidase, aber keine Invertase bildet, so erhaltener Mikroorganismus and seine Verwendung
DE68913587T2 (de) Extraktion von menschlichem Interleukin-4 aus Bakterien.
DE69225009T2 (de) Eine asymmetrisch aktive Esterase kodierendes Gen
DE68916444T2 (de) Sekretorische e-coli-stämme.
DE3735379A1 (de) Rna-polymerase-gen, verfahren zu seiner herstellung und mikroorganismus mit diesem gen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHAGE BIOTECHNOLOGY CORP., LAS VEGAS, NEV., US

Owner name: CARDIOVASCULAR BIO THERAPEUTICS,INC., LAS VEGA, US